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Abstract: Resveratrol is a naturally occurring polyphenol that provides several health benefits
including cardioprotection and cancer prevention. However, its biological activity is limited by
a poor bioavailability when taken orally. The aim of this work was to evaluate the capability of
casein nanoparticles as oral carriers for resveratrol. Nanoparticles were prepared by a coacervation
process, purified and dried by spray-drying. The mean size of nanoparticles was around 200 nm
with a resveratrol payload close to 30 µg/mg nanoparticle. In vitro studies demonstrated that the
resveratrol release from casein nanoparticles was not affected by the pH conditions and followed
a zero-order kinetic. When nanoparticles were administered orally to rats, they remained within the
gut, displaying an important capability to reach the intestinal epithelium. No evidence of nanoparticle
“translocation” were observed. The resveratrol plasma levels were high and sustained for at least 8 h
with a similar profile to that observed for the presence of the major metabolite in plasma. The oral
bioavailability of resveratrol when loaded in casein nanoparticles was calculated to be 26.5%, 10 times
higher than when the polyphenol was administered as oral solution. Finally, a good correlation
between in vitro and in vivo data was observed.
Keywords: resveratrol; casein; nanoparticles; oral delivery; mucus-permeating; bioavailability;
resveratrol-O-3-glucuronide
1. Introduction
Resveratrol (Rsv) is a nutraceutical named trans-3,4′,5-trihydroxystilbene and consists of two
aromatic rings which are linked through a methylene bridge. It is a natural polyphenol found in more
than 70 species of plants, particularly in grapes, blueberries and peanuts [1]. One of the more important
sources for human consumption is red wine, although its content depends on several factors including
the grape variety, vineyard location, cultivation system, climate and soil type and production process
among others [2]. The interest of the scientific community in resveratrol was originally sparked by
epidemiological studies, that evidenced an inverse relationship between moderate wine consumption
and cardiovascular disease (the so-called “French Paradox”) [3,4] and by the fact that cancer preventive
properties of resveratrol was observed both in vitro and in vivo [5].
The mechanism by which resveratrol exerts such arrange of beneficial effects across species and
disease models is not yet elucidated. However, these effects would be related to the capability of this
polyphenol to enhance the nitric oxide bioactivity and/or its inhibitory effect on platelet COX-1 and
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NF-κB [6]. In this context, resveratrol would block the platelet aggregation by its ability to specifically
inhibit prostaglandins synthesized by COX-1 [7] such as thromboxane A2, which is a potent inducer of
platelet aggregation and vasoconstrictor [8]. Apart from the vasorelaxant effect due to the inhibition of
thromboxane A2 synthesis, resveratrol would also induce vasodilatation by its ability to enhance nitric
oxide signaling in the endothelium [9], leading to a reduction in its inactivation rate. On the other hand,
it has been demonstrated that resveratrol possesses cancer chemopreventive and chemotherapeutic
activity [5,10]. This fact would be related with its inhibitory effect over cyclooxygenase [2], NF-κB [11]
and protein kinase C [12], among others. Moreover, resveratrol would inhibit the tumor-induced
neovascularization acting as an antiangiogenic agent [10,13].
Despite all these advantages, resveratrol also possesses some drawbacks that limit its use.
Thus, resveratrol shows a very low aqueous solubility (0.02–0.03 mg/mL [14]. In addition, resveratrol
is very sensitive to degradation by exposure to oxygen, light, temperature and oxidative enzymes [6].
Under these circumstances trans-resveratrol may be isomerized to the less active cis-version, reducing
its activity [15,16]. Another limiting and important factor is its poor oral bioavailability (less than 5%)
due, at least in part, to its rapid metabolism and elimination [17]. Resveratrol suffers a presystemic
metabolism through first-pass glucuronidation and sulfate conjugation of the phenolic groups in the
intestinal enterocytes and liver. In addition, resveratrol hydrogenation of the aliphatic trans double
bond by the intestinal microbiota was shown. The major resveratrol metabolites encountered after
oral administration of resveratrol includes resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide and
dihydroresveratrol conjugates which results in low oral bioavailability [6,18]. Very little is known about
the bioactivity of these metabolites; although resveratrol-3-O-sulfate would show a strong in vitro
anti-estrogenic activity [19].
The aim of this work was to prepare, characterize and evaluate the capability of casein
nanoparticles as carriers for the oral delivery of resveratrol. Casein is a food-grade protein that
may be transformed into nanoparticles under mild conditions [20] and, thus, produce devices with
interest for food fortification as well as for nutraceutical and pharmaceutical applications. In addition,
milk caseins display a high affinity for polyphenols, including resveratrol [21,22], and can bind these
types of molecules via hydrophilic and hydrophobic interactions. Furthermore, in the presence of
proteins, resveratrol would be more protected from trans-to-cis isomerization than when it is in the
free form [23,24]. More particularly, this work reports the capability of these devices to promote the
oral bioavailability of resveratrol in rats.
2. Results
2.1. Characterization of Nanoparticles
Table 1 shows the physicochemical characteristics of casein nanoparticles used in this study.
For empty nanoparticles, the mean size was around 140 nm and the zeta potential was negative.
When resveratrol was encapsulated into casein nanoparticles, the resulting average size significantly
increased (210 nm vs. 140 nm) whereas the negative zeta potential was slightly more negative than for
empty nanoparticles (−19 mV vs. −12 mV). The resveratrol loading was calculated to be 31 µg/mg
nanoparticles, with an encapsulation efficiency close to 70%.
Table 1. Physicochemical characteristics of nanoparticles employed in this study.
Formulation Size (nm) PDI (nm) Zeta Potential (mV) Rsv Loading (µg/mg) E.E. (%)
NP-C 138 ± 6 0.19 ± 0.02 −12 ± 1
Rsv-NP-C 210 ± 3 0.20 ± 0.02 −19 ± 1 31 ± 1 68 ± 3
NP-C: empty nanoparticles; Rsv-NP-C: resveratrol-loaded casein nanoparticles. Data expressed as mean ± SD, n = 5.
The morphological analysis by field emission scanning electron microscopy (Figure 1)
showed that resveratrol-loaded casein nanoparticles consisted of homogeneous populations of
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polyhedral nanoparticles with rough surface and apparent size similar to that obtained by photon
correlation spectroscopy.
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Figure 1. Scanning Electron icroscopy microphotographs obtained from resveratrol-loaded
casein nanoparticles.
2.2. In Vitro Release Studies
Resveratrol release kinetics from casein nanoparticles were evaluated in simulated physiological
fluids. For this purpose, nanoparticles were initially incubated during the first 2 h in simulated gastric
fluid (SGF) and, then, in simulated inte inal fl id (SIF). Figure 2 r presents the r lease profile of
resveratrol from casein nanopa ticles as the cumulative per entage f the cargo released versus time.
Interestingly, the release of resveratrol from casein nanoparticles was found to be independent of the
pH conditions. During the first 2 h, under SGF (pH 1.2), about 30% of the loaded resveratrol was
released. Then, four hours later (in SIF) the amount released was close to 80% of the total content
of resveratrol. Nine hours after the beginning of the experiment, almost the total amount of the
encapsulated resveratrol was released from nanoparticles.
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Figure 2. Resveratrol release profile from casein nanoparticles after incubation in si ulated gastric (SGI,
pH 1.2; 0–2 h) and simulated intestinal fluids (SIF, pH 6.8; 2–24 h) under sink conditions. Data expressed
as mean ± SD, n = 3.
The resveratrol release data from casein nanoparticles fitted well to both the Korsmeyer-Peppas
model (KKT = 0.14 ± 0.01 h−n; n = 1.02 ± 0.04; R2 > 0.99) and the zero-order kinetics equation
(K = 0.14 ± 0.00 h−1; R2 > 0.99). These results suggest that the release mechanism of resveratrol from
casein nanoparticles would be ruled by the erosion of the nanoparticulate matrix.
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2.3. In Vivo Biodistribution Study of Casein Nanoparticles
Figure 3 shows the biodistribution of casein nanoparticles, at different times after their oral
administration to rats. Two hours after their oral administration, casein nanoparticles were visualized
in the stomach. Twenty-two hours later, the radioactivity was found in the distal part of gastrointestinal
tract; whereas, 2 days post administration, the radioactivity had disappeared. For the control
formulation of gallium-67, during the 48-h in which the experiment took place, the radiolabeled
agent (gallium-67 citrate) was always visualized in the stomach. This finding would be related with
the ready formation of Ga(OH)3 and GaO(OH), that possess a very low aqueous solubility over a wide
pH range [25].
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Figure 3. Comparison of the biodistribution of casein nanoparticles radiolabeled with gallium
(NP-NOTA-Ga) and the radiomarker used as control (Gallium-67 citrate). Panels (A) and (B) show
gammacamera images after oral administration of NP-NOTA-Ga (rat on the right) and control (rat on
the left) at 2 and 24 h post administration.
Figure 4 shows fluore cence microscopy images of jejunum samples, 2 h after the oral
administration to animals of fluorescently labelled nanoparticles. The control, an aqueous suspension
of Lumogen® red, was visualized as agglomerates in the intestinal lumen of animals (Figure 4A,B).
On the contrary, casein nanoparticles were observed within the mucus layer and in close contact with
the surface of the epithelium (Figure 4C,D).
Int. J. Mol. Sci. 2018, 19, 2816 5 of 17
Int. J. Mol. Sci. 2018, 19, x  5 of 17 
 
 
Figure 4. Fluorescence microscopy images of rat jejunum samples, two hours after the oral administration 
of either an aqueous suspension of Lumogen® red (A,B) or casein nanoparticles labelled with Lumogen® 
red (C,D). Nuclei of cells were stained blue with DAPI (4′,6-diamidino-2-phenylindole). 
2.4. Pharmacokinetic Studies in Wistar Rats 
The plasma concentration-time profile of a resveratrol solution (in a mixture of PEG-400 and 
water; 1:1 by vol.) after its intravenous administration of a single dose (15 mg/kg) to rats is shown in 
Figure 5. Data were adjusted to a non-compartmental model. As it can be seen, the resveratrol plasma 
concentration decreased rapidly in a biphasic way, and no quantifiable levels were detected 8 h post 
administration. The peak plasma concentration (Cmax) of resveratrol was around 15 μg/mL. Values 
obtained for AUC (Area Under the Curve) and half-life (t1/2) were 11.4 μg h/mL and 2.0 h, respectively. 
The resveratrol clearance and its distribution volume were calculated to be 0.2 L/h and 0.6 L, 
respectively (Table 2). 
 
Figure 5. Resveratrol plasma concentration vs. time after a single i.v. administration of a resveratrol 
solution (dose 15 mg/kg). Data expressed as mean ± SD, (n = 6). 
0 2 4 6 8 10
100
1,000
10,000
100,000
Rs
v p
las
ma
 co
nc
en
tra
tio
n (
ng
/m
L)
Time (h)
Figure 4. Fluorescence microscopy images of rat jejunum samples, two hours after the oral administration
of either an aqueous suspension of Lumogen® red (A,B) or casein nanoparticles labelled with Lumogen®
red (C,D). Nuclei of cells were stained blue with DAPI (4′,6-diamidino-2-phenylindole).
2.4. Pharmacokinetic Studies in Wistar Rats
The plasma concentration-tim profile of a resveratrol solution (in a mixture of PEG-400 and
water; 1:1 by vol.) ft its in ravenous administration of a single do (15 mg/kg) t rat is shown
in Figure 5. Data were adjusted to a non-compartmental model. As it can be seen, the resveratrol
plasma concentration decreased rapidly in a biphasic way, and no quantifiable levels were detected
8 h post administration. The peak plasma concentration (Cmax) of resveratrol was around 15 µg/mL.
Values obtained for AUC (Area Under the Curve) and half-life (t1/2) were 11.4 µg h/mL and 2.0 h,
respectively. The resveratrol clearance and its distribution volume were calculated to be 0.2 L/h and
0.6 L, respectively (Table 2).
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Table 2. Pharmacokinetic parameters of resveratrol formulated as solution, after either intravenous or
oral administration (Rsv-IV and Rsv-Sol, respectively), oral suspension (Rsv-Susp) or loaded in casein
nanoparticles (Rsv-NP-C) at a single dose of 15 mg/kg bw to Wistar rats.
Formulation Route Cmax (µg/mL) Tmax (h)
AUC
(µg h/mL) t1/2 (h) Cl (mL/h) Vd (mL) MRT (h) Fr (%)
Rsv-IV iv 15.2 ± 5.18 0.1 ± 0.0 10.4 ± 3.80 2.0 ± 0.5 199.4 ± 89.81 569.2 ± 221.4 2.4 ± 1.0 100
Rsv-Sol po 0.20 ± 0.02 ** 0.6 ± 0.2 0.28 ± 0.13 0.3 ± 0.2 ** 386.7 ± 224.9 112.3 ±103.6 ** 1.3 ± 0.8 * 2.6
Rsv-Susp po - - - - - - - -
Rsv-NP-C po 0.29 ± 0.07 **† 1.8 ± 1.3 2.76 ± 1.64**†† 2.7 ± 0.7
†† 161.8 ± 69.86 661.7 ± 242.9 †† 8.2 ± 3.7 **†† 26.5
Data are expressed as mean± SD (n = 6). Cmax: peak plasma concentration; Tmax: time to reach plasma concentration;
AUC: Area under the curve; t1/2: half-life of the terminal phase; Cl: Clearance; MRT: mean residence time Fr: relative
oral bioavailability. * Significant differences vs. Rsv-IV (p < 0.05) (Mann-Whitney-U); ** Significant differences vs.
Rsv-IV (p < 0.01) (Mann-Whitney-U); † Significant differences vs. Rsv-Sol (p < 0.05) (Mann-Whitney-U); †† Significant
differences vs. Rsv-Sol (p < 0.01) (Mann-Whitney-U).
Figure 6 shows the plasma concentration levels of resveratrol as a function of time after a single
oral administration of 15 mg/kg to male Wistar rats of the different formulations tested (solution,
suspension and casein nanoparticles). When the aqueous suspension of resveratrol was administered
orally, no quantifiable levels of the polyphenol were detected in the plasma of laboratory animals.
For the solution of resveratrol (Rsv-Sol) orally administered, the polyphenol plasma levels were only
quantifiable during the first 4 h post administration. Interestingly, when resveratrol was loaded in
casein nanoparticles, the polyphenol plasma levels were quantified during 24 h. In addition, at least
during the first 8 h, casein nanoparticles provided sustained levels of resveratrol in plasma.
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Figure 6. Resv ratrol plasma concentration vs. i fter a single oral adminis rati n of 15 mg/kg for
the different formulations tested. (i) Resveratrol PE 400:water solution ( ); (ii) Resveratrol-loaded
casein nanoparticles (). Data expressed as mean ± SD, (n = 6).
Pharmacokinetic parameters of resveratrol in plasma, after its intravenous or oral administration,
are listed in Table 2. When resveratrol was administrated as a PEG400:water solution by the oral route,
the AUC was around 0.29 µg h/mL. In the case of resveratrol encapsulated in casein nanoparticles,
the AUC was found to be significantly higher than for the conventional formulation (p < 0.01).
In addition, both MRT and t1/2 values of resveratrol in plasma after the administration of the
nanoparticles was f und to be around 6-fold higher than when r sveratrol was administered as
oral solution. O the ot r hand, th volume of distribution of th polyphen l as well as the resveratrol
clear nce and t1/2 when administered in casein nanoparticles we similar to the lues calculated
after its administration by the intravenous route. Finally, the relative oral bioavailability of resveratrol
when incorporated into nanoparticles achieves 27%, about 10-times higher than the value obtained
when the polyphenol was formulated as oral solution.
Figure 7 shows the concentration of one of the main metabolites of resveratrol
(resveratrol-O-3-glucuronide) in plasma as a function of time, after the administration of a single
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dose of resveratrol encapsulated in nanoparticles (oral) or dissolved in a PEG400:water solution (oral
and intravenous). As expected, the metabolite plasma levels were higher than those observed for
the polyphenol (Figure 6). However, the profiles of the curves were similar for both compounds,
irrespective of the route of administration.
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Figure 7. Resv rat ol-O-3 glucuroni a concentration vs time after the administration of
a single dose of resveratrol (15 mg/ in nanoparticles (oral) or dissolved in a PEG400:water
mixture (oral and intravenously). (i) esveratrol solution intravenously administered (Rsv-IV) ( );
(ii) resveratrol solution orally administered (Rsv-Sol) (); (iii) resveratrol-loaded casein nanoparticles
orally administered (Rsv-NP-C) (N). Data expressed as mean ± SD, (n = 6).
When resveratrol was administered intravenously, its metabolite concentration reached 42 µg/mL
(Cmax) and, th n, its levels d creased rapidly reaching a very low amount in plasma only 8 h post
administration. The AUC value was calculated to be 197 µg h/mL. For the solution of resveratrol
orally administered, the Cmax of resveratrol-O-3-glucuronide in plasma was 2-times lower (22 µg/mL)
than when administered intravenously. Moreover, the metabolite was only detected and quantified
during the first 8 h after administration. The AUC value was calculated to be 104 µg h/mL.
Concerning Rsv-NP-C, the profile of the curve representing the concentration of
resveratrol-O-3-glucuronide in plasma vs time was characterized by increasing levels of the metabolite
in plasma until reaching a plateau (around 20 µg/mL). Then, the plateau was maintained for at least
8 h. Twenty-four hours after the administration of casein nanoparticles, quantifiable but low levels of
the resveratrol metabolite were found. The AUC of resveratrol-O-3-glucuronide, when the polyphenol
was administered orally after its encapsulation in casein nanoparticles (295 µg h/mL), was found to be
around 2-times higher than when the resveratrol was iv administered (p < 0.05) and 3-times higher
than when the drug was orally administered as a PEG400:water solution (p < 0.01).
2.5. In Vitro-In Vivo Correlations
The relationship between the in vitro dissolution data and the in vivo pharmacokinetic data was
examined by plotting the percentage of drug released until 8 h vs. the fraction of intact resveratrol
absorbed during the same period (Figure 8). A good linear regression relationship was observed
between the fraction of resveratrol released and the fraction of resveratrol absorbed (R2 = 0.996).
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3. Discussion
This work reports the preparation and evaluation of casein nanoparticles as carriers for resveratrol.
The use of casein may offer some advantages, including its capability to be used to produce
nanoparticles as well as its ability to bind polyphenols in a non-specific way [21,22] and its protective
effect against the inactivation of resveratrol by trans-to-cis isomerization [23,24].
The resulting resveratrol-loaded casein na oparticles were polyhedral (F gure 1) and displayed
a size of around 200 nm with resveratrol content close to 31 µg/mg nano article. This result is at least
similar to that reported by Jose and collaborators that used solid lipid nanoparticles for the delivery of
this polyphenol [26]. In other recent works (using chitosan microspheres [27], lipid nanoparticles [28]
or niosomes [29]), reported resveratrol loadings between 2- and 3-times lower than for the casein
nanoparticles describ d here.
Interestingly, the releas of resveratr l from casein nanoparticles was indep ndent of the pH
conditions. Moreover, the cumulative amount of resveratrol released from nanoparticles followed
a zero-order kinetic (Figure 2). Thus, it is possible to speculate that the entry of water inside the casein
nanoparticles would induce a relaxation and/or erosion of the nanoparticles matrix that would favor
the resveratrol diffusion. A similar explanation was proposed in other works, in which they described
the release of the biologically active compound as a result of the hydrolytic degradation of the sodium
caseinate matrix through the entry of water inside the nanoparticl s [30,31].
In the present study, the plasma concentrations of resveratrol provided by a conventional
oral solution of the polyphenol in a mixture of PEG400 and water were low. With this solution,
the oral bioavailability of resveratrol was calculated to be 2.6%. The highest recorded concentrations
of resveratrol in plasma occurred 30 min after administration, and values returned to baseline
within 4 h (Figure 6). These results e in line with the findings previously rep rted by
other research groups [32–34]. This low oral bioavailability would be the result of the effect
of UDP-glucuronosyltransferase and sulfotransferases on resveratrol. These enzymes, localized
in the liver [35] and small intestine [17], would transform resveratrol in its glucuronides and
sulfates derivatives.
On the other h nd, casein nanoparticles provid higher a d mo e prolonged resveratrol plasma
levels than th oral solu ion. Mor important, the resveratrol plasma levels we e sustained for at
least 8 h post administration and significant amounts of the polyphenol was also quantified 24 h after
the administration of nanoparticles to rats (Figure 6). Consequently, the relative oral bioavailability
of resveratrol when administered after its encapsulation in casein nanoparticles was found to be
10-times higher than when formulated as oral solution (Table 2). This improvement in the relative oral
bioavailability of resveratrol observed for casein nanoparticles was higher than other improvements
reported in the literature. Thus, using SNEDDS (Self Nanoemulsifying Drug Delivery Systems),
the resveratrol bioavailability was found to be 5-fold higher than the control formulation (an aqueous
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suspension of the polyphenol) [36]. In a similar way, solid lipid nanoparticles have also been proposed
as carriers for improving the oral bioavailability of resveratrol [37]. In this particular case, these lipid
nanoparticles offered an 8-times higher oral bioavailability than the control formulation (an aqueous
suspension. In another interesting work, Ramalingam and Ko [38] defined a relative oral bioavailability
of resveratrol of about 4-times higher from solid nanoparticles than that observed for a conventional
suspension of the polyphenol.
Another important aspect is the effect of formulating resveratrol in casein nanoparticles on its
primary pharmacokinetic parameters. Thus, with Rsv-NP-C, the values of the polyphenol half-life in
plasma (t1/2), clearance (Cl) and volume of distribution (Vd) were similar to those obtained after its
intravenous administration as solution. These findings would be evidence that nanoparticles remain
within the gut of animals and just the released resveratrol was absorbed. This fact was confirmed by
the biodistribution studies. Thus, radiolabeled casein nanoparticles, after their administration to rats,
remained in the gastrointestinal tract and no proofs of nanoparticle “translocation” or absorption was
observed (absence of signals in the liver, spleen, lungs or kidneys of animals; Figure 3). Furthermore,
the fluorescently labelling of casein nanoparticles with Lumogen® red allow us to visualize a fluorescent
signal in the area in which the epithelium cells are located (Figure 4C,D). All of this suggests the
mucus-permeating properties of casein nanoparticles and their capability to reach the surface of the
epithelium in which the cargo (resveratrol) would be released. The release process would be drive
by enzymatic digestion facilitating the erosion of the nanoparticle matrix and the elimination of
nanoparticles. This would be in line with the work of Elzoghby and collaborators [39], in which they
described a certain capability of casein nanoparticles to reach the surface of intestinal cells. After the
release of resveratrol from casein nanoparticles, it would be absorbed through the enterocytes and,
at least, a fraction would escape from its rapid enzymatic metabolization. In rats, the major metabolite
of resveratrol is the glucuronide conjugate (resveratrol-O-3-glucuronide) [40] that, in our work, it was
quantified in plasma. Interestingly, for the different formulations tested, the profile of the curves
for the metabolite plasma levels (Figure 7) was similar to that observed for resveratrol (Figure 6).
The highest AUC for the metabolite was found when resveratrol was administered encapsulated in
casein nanoparticles (about 3-times higher than for Rsv-Sol). This fact demonstrated the controlled
release properties of these carriers that can sustain the plasma concentration of the polyphenol for at
least 8 h. Nevertheless, these elevated levels of the metabolite in plasma do not correlated adequately
with a relatively high oral bioavailability observed with Rsv-NP-C. One possible explanation would
be a saturation of the biotransformation phenomenon due to the presence of high local resveratrol
concentrations. The saturation of glucuronosyltransferases, involved in the presystemic metabolism
of resveratrol, by high levels of this polyphenol have been described previously [41,42]. Another
possibility would be that the delivery of resveratrol via casein nanoparticles would facilitate to
bypass the presystemic metabolism of this lipophilic compound by promoting its intestinal lymphatic
transport. This possibility has been proposed for lipophilic compounds that may associate with
lipoproteins, facilitating their entry to intestinal lymphatic vessels and, then, transported to systemic
circulation [43].
Another important point to highlight is the good correlation found between the in vitro
(resveratrol release from nanoparticles) and in vivo (resveratrol plasma levels) data (Figure 8).
This finding would corroborate the capability of casein nanoparticles to carry resveratrol until the
surface of the absorptive membrane and, once there, to control its release at a rate that would favor its
absorption and entry in the circulation.
4. Materials and Methods
4.1. Reagents
Sodium caseinate was purchased from ANVISA (Madrid, Spain). Resveratrol, lysine, mannitol,
polyethylene glycol 400 (PEG 400), DAPI (4′,6-diamidino-2-phenylindole), formaldehyde and Tween
Int. J. Mol. Sci. 2018, 19, 2816 10 of 17
20, were obtained from Sigma-Aldrich (Darmstadt, Germany). Calcium chloride, ethanol, methanol,
acetonitrile and acetic acid HLPC (High Liquid Performance Chromatography) grade were from
Merck (Darmstadt, Germany). Resveratrol-3-O-D-glucuronide was from @rtMolecule (Cedex-France).
Gallium-67 citrate from IBA Molecular SA (Pamplona, Spain) and NOTA from Macrocyclics Inc.,
(Dallas, TX, USA). Lumogen® F red 305 was from Kremer (Aichstetten, Germany). Tissue-Tek® OCT
(Optimal Cutting Temperature) compound was obtained from Sakura (Alphen, The Netherlands).
4′,6-diamidino-2-phenylindole (DAPI) was obtained from Biotium Inc. (Madrid, Spain). All reagents
and chemicals used were of analytical grade.
4.2. Preparation of Resveratrol-Loaded Nanoparticles
Resveratrol-loaded casein nanoparticles (Rsv-NP-C) were prepared as described previously [20]
with some modifications. Briefly, 600 mg sodium caseinate and 60 mg lysine were dissolved in 40 mL
purified water. In parallel, 26 mg resveratrol were dissolved in 2.6 mL ethanol and added to the casein
solution. The mixture was incubated for 30 min under magnetic stirring at room temperature and
the nanoparticles were formed by the addition of 24 mL of an aqueous solution of calcium chloride
(0.8% w/v). The nanoparticles were purified by ultrafiltration (polysulfone membrane cartridge,
50 kDa; Medica SPA, Medolla, Italy) before adding an aqueous solution of mannitol as protectant
(20 mL; 100 mg/mL). Finally, the suspensions were dried in a Mini Spray Drier B-290 apparatus
(Büchi Labortechnik AG, Flawil, Switzerland) under the following experimental conditions: (i) inlet
temperature of 90 ◦C; (ii) outlet temperature 45–50 ◦C; (iii) air pressure: 2–5 bar; (iv) pumping rate of
2–6 mL/min; (v) aspirator of 100% and (vi) air flow at 900 L/h.
Empty nanoparticles (NP-C) were prepared in the same way as described above but in the absence
of resveratrol.
4.3. Preparation of Resveratrol Conventional Formulations
Two different formulations of resveratrol were also prepared. The first one consisted of a solution
of the polyphenol in a mixture of PEG 400 and water (Rsv-Sol). For this purpose, 37.5 mg resveratrol
were dissolved in 5 mL PEG 400 under magnetic stirring. Then 5 mL water were added and the
mixture was maintained under agitation in the dark for 10 min.
The second one was an extemporary suspension of resveratrol (Rsv-Susp) in purified water.
Briefly, 37.5 mg resveratrol were weighed and dispersed in 10 mL purified water under magnetic
agitation for 10 min. The suspension was used after visual inspection for absence of aggregates (Size:
21.5 ± 9.24 µm; PDI: 0.510 ± 0.042).
4.4. Characterization of Resveratrol-Loaded Nanoparticles
4.4.1. Physicochemical Characterization
The mean size and the zeta potential of nanoparticles were determined by photon correlation
spectroscopy (PCS) and electrophoretic laser Doppler anemometry, respectively, using a Zetaplus
apparatus (Brookhaven Instruments Corporation, Holtsville, NY, USA). The diameter of the
nanoparticles was determined after dispersion in ultrapure water (1:10) and measured at 25 ◦C
by dynamic light scattering angle of 90◦. The zeta potential was determined as follows: 200 µL of the
samples were diluted in 2 mL of a 0.1 mM KCl solution adjusted to pH 7.4.
The morphology of the nanoparticles was studied using a field emission scanning electron
microscopy (FE-SEM) in a Zeiss DSM940 digital scanning electron microscope (Oberkochen, Germany)
coupled with a digital image system (Point Electronic GmBh, Halle, Germany). The yield of the process
was calculated by gravimetry [20].
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4.4.2. Resveratrol Analysis
Resveratrol was quantified by HPLC-UV [44]. Analysis were carried out in an Agilent model 1100
series LC and diode-array detector set at 306 nm. Data were analyzed in chemstation G2171 program
(B.01.03). The chromatographic system was equipped with a reverse phase 150 mm × 2.1 mm C18
Alltima column (particle size 5 µm; Altech, Flemington, NJ, USA) and a Gemini C18 support AJO-7596
precolumn. The mobile phase was a mixture of water, methanol and acetic acid in a gradient condition
and pumped at 0.25 mL/min. The column was heated at 40 ◦C and the injection volume was 10 µL.
Under these conditions, the run time for resveratrol was 22.8 ± 0.5 min. Calibration curves in ethanol
75% were designed over the range of 1–100 µg/mL (R2 = 0.999).
For analysis, 10 mg nanoparticles were dispersed in 1 mL water before centrifugation at 17,000 rpm
for 20 min at 4 ◦C, the supernatants were analyzed to determine the amount of free resveratrol (not
encapsulated). The amount of resveratrol loaded in the nanoparticles was calculated by subtracting the
amount of resveratrol quantified in the supernatant from the theoretical total amount of the polyphenol
employed in the preparation of nanoparticles. Each sample was analyzed by triplicate and the results
were expressed as the amount of resveratrol (in µg) per mg of nanoparticles. The encapsulation
efficiency (E.E.) was calculated as follows:
E.E. (%) =
(Rsvt − Rsvs)
Rsvt
× 100 (1)
in which Rsvt is the total theoretical amount of resveratrol in the formulations and Rsvs corresponds to
the amount of resveratrol quantified in the supernatants.
4.5. In Vitro Release Studies
In vitro release experiments were conducted under sink conditions at 37 ◦C using simulated
gastric (SGF) and intestinal fluids (SIF), containing 0.5% Tween 20 to increase the aqueous solubility
of the polyphenol. The studies were performed under agitation in a slide-A-Lyzer® Dialysis cassette
10.000 MWCO (Thermo scientific, Rockford, IL, USA). The cassette was filled with 3 mg resveratrol
loaded in casein nanoparticles, previously dispersed in 5 mL water. Then, the cassette was introduced
in a vessel containing 500 mL SGF (pH 1.2: 37 ◦C) under magnetic agitation. After 2 h in SGF,
the cassette was introduced in another vessel containing 500 mL SIF (pH 6.8; 37 ◦C, under agitation).
At different time points, samples tubes were collected and filtered with 0.45 µm filters (Thermo,
Chino, CA, USA) before quantification.
The amount of resveratrol released from the formulations was quantified by HPLC. Calibration
curves of free resveratrol in water containing 0.5% tween 20 at pH 1.2 and 6.8 were performed, over the
range 0.05–6 µg/mL (R2 > 0.999) in both cases. To ascertain the drug release mechanism, the obtained
data were fitted to the Korsmeyer-Peppas (Equation (2)) and the zero-order (Equation (3)) models.
Mt/M∞ = KKP × tn (2)
where Mt/M∞ is the drug release fraction at time t, KKP is a constant incorporating the structural
and geometric characteristics of the matrix and n is the release exponent indicative of the drug
release mechanism. The value of n indicates the mechanism of the release [45]. If the value is
around 0.5, the mechanism is Case I (Fickian) diffusion, a value between 0.5 and 0.89 indicates
anomalous (non-Fickian) diffusion suggesting a combination of mechanisms diffusion and erosion.
Values of n between 0.89 and 1 indicate Case II transport, which involves a release mechanism ruled
by erosion/relaxation of the matrix.
Mt/M∞ = KZO × t (3)
where Mt/M∞ is the drug release fraction at time t, and KZO is the zero-order release constant.
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To fit the experimental data to the previous models, only the first portion of the release profile
was used (Mt/M∞ ≤ 0.6) [46].
4.6. Labelling of Casein Nanoparticles
4.6.1. Radiolabeling of Casein Nanoparticles (NP-NOTA-Ga)
Casein nanoparticles were radiolabeled with 67Gallium (67Ga). Briefly, casein molecules were
first tagged with p-SCN-Bn-NOTA (NOTA). Thus, 50 mg sodium caseinate and 5 mg NOTA were
incubated for 24 h in 5 mL sodium bicarbonate solution (pH 9.5). After this reaction, the protein was
purified by dialysis to remove the inorganic salts presented in the buffered medium and the free NOTA
chelator. After this purification process, the protein derivative (casein-NOTA) was lyophilized. Tagged
(50 mg) and untagged protein (450 mg) were used to prepare casein nanoparticles following the same
procedure described above (see Section 4.2). Finally, NOTA nanoparticles (NOTA-NP) were labelled
by citrate-NOTA transquelation with gallium-67 citrate [47].
4.6.2. Fluorescently Labelling of Casein Nanoparticles (LR-NP)
Lumogen red-loaded nanoparticles were prepared by adding 2.5 mg Lumogen® F Red 305 in
acetone (5 mL) to the solution of sodium caseinate and lysine. Then, casein nanoparticles were formed
by the addition of a calcium chloride water solution. The resulting nanoparticles were purified and
dried in the Spray Drier apparatus under the same conditions described above (see Section 4.2).
4.7. In Vivo Biodistribution Studies
Studies were carried out in male Wistar rats (200–250 g) obtained from Harlan (Barcelona, Spain)
and the protocols were approved by the Ethical Committee for Animal Experimentation of the
University of Navarra (protocol numbers 117-12 [31 October 2012] and 059-13 [21 June 2013]). Prior to
the experiments, animals were placed in metabolic cages and drink was provided ad libitum.
For radiolabeled nanoparticles, animals received a single dose of nanoparticles (10 mg
gallium-67-citrate-NP). Animals were anesthetized with isofluorane and placed in prone position
on the gamma camera. The SPECT-CT images were obtained 2 and 24 h after the administration
of the radiolabeled nanoparticles in a Symbia® gamma camera (Siemens Medical Systems,
Malvern, PA, USA).
For fluorescently labelled nanoparticles, 30 mg nanoparticles in 1 mL water were administered to
animals. Two hours later, the animals were sacrificed, and their gastrointestinal tract was removed.
Jejunum portions of 1 cm were stored in the tissue proceeding medium OCT and frozen at −80 ◦C.
Each portion was then cut into 5-µm sections on a cryostat and attached to glass slides. Finally,
the samples were fixed with formaldehyde and incubated with DAPI for 15 min. The samples were
examined in a fluorescence microscope (Axioimager M1, Zeiss, Oberkochem, Germany) with a coupled
camera (Axiocam ICc3, Zeiss) and fluorescent source (HBO 100, Zeiss).
4.8. In Vivo Pharmacokinetic Studies in Wistar Rats
Pharmacokinetic studies were performed in male Wistar rats (200–250 g) obtained from Harlan
(Barcelona, Spain). Studies were approved by the Ethical Committee for Animal Experimentation
of the University of Navarra (protocol number 014-10 [12 February 2010]) in accordance with the
European legislation on animal experiments. Before administration, animals were fasted overnight
allowing free access to water.
For the pharmacokinetic study, rats were randomly divided into 4 groups (n = 6). The experimental
groups that received the resveratrol formulations orally were: (i) resveratrol aqueous suspension
(Rsv-Susp); (ii) resveratrol solution in PEG 400:water (Rsv-Sol) and (iii) resveratrol-loaded casein
nanoparticles (Rsv-NP-C). As control, a group of animals received the resveratrol solution
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intravenously. Each animal received the amount of resveratrol equivalent to a dose of 15 mg/kg
bw either orally or intravenously via tail vein.
Blood samples were collected at set times after administration (0, 10 min, 30 min, 1, 2, 4, 6, 8,
24 and 48 h) in specific plasma tubes (Microvette® 500K3E, ref 20.1341. SARSTEDT, Nümbrecht
Germany). Blood volume was recovered intraperitoneally with an equal volume of normal saline
solution pre-heated at body temperature. Samples were immediately centrifuged at 10,000 rpm for
10 min. Plasma was separated into clean tubes and kept frozen at −80 ◦C until analysis of both
resveratrol and resveratrol-3-O-D-glucuronide.
4.8.1. Determination of Resveratrol and Rsv-3-O-D-Glucuronide Plasma Concentration by HPLC
The amount of resveratrol was determined by high pressure liquid chromatography
with UV detection (HPLC-UV), following an analytical method previously published with
minor modifications [48]. Analysis were carried out in an Agilent model 1100 series LC and
diode-array detector set at 306 nm. The data were analyzed Chemstation G2171 program (B.01.03).
The chromatographic system was equipped with a reversed-phase 250 mm × 2.1 mm C18 Kromasil
(particle size 5 µm) column and a Gemini C18 support AJO-7596 precolumn. The mobile phase,
pumped at 0.5 mL/min, was a mixture of water, methanol and acetic acid (50:45:5 by vol.) in isocratic
conditions. The column was placed at 30 ◦C and the injection volume was 30 µL. Under these
conditions, the run time for resveratrol-3-O-D-glucuronide and resveratrol was 6.2 ± 0.5 min and
12.6 ± 0.5 min, respectively.
For analysis, an aliquot of plasma (100 µL) was mixed with 50 µL HCl (0.1 N) and 500 µL
acetonitrile to precipitate proteins. The mixture was shaken vigorously at 2500 rpm (Hettichzentrifugen,
Tuttlingen, Germany) for 10 min. Then, the samples were centrifuged at 4000 rpm for 10 min and
the supernatant was recovered and evaporated to dryness at 25 ◦C for 30 min in an Automatic
environmental Speed vac® system (Savant apparatus, Holbrook, NY, USA). Finally, 100 µL of an
acetonitrile water mixture (1:1 by vol.) were added to reconstitute the extract. The resulting solution
was filtered with 0.45 µm filters (Thermo, Chino, CA, USA) and injected in the HPLC system.
For quantification, calibration curves were designed over the range between 2 and 70 µg/mL,
for the metabolite, and between 50 and 3000 ng/mL for resveratrol (R2 > 0.99). The standards were
prepared by adding (resveratrol or resveratrol-3-O-D-glucuronide) in 500 µL acetonitrile to 100 µL free
plasma following the same extraction method described above.
Under these experimental conditions, the limit of quantification for resveratrol was calculated to
be 70 ng/mL. For the metabolite, the limit of quantitation of this technique was established as 4 µg/mL.
Linearity, accuracy and precision values during the same day (intraday assay) at low, medium and high
concentrations of resveratrol and resveratrol-3-O-D-glucuronide were always within the acceptable
limits (less than 15%).
4.8.2. Pharmacokinetic Data Analysis
Pharmacokinetic analysis was performed using a non-compartmental model with the WinNonlin
5.2 software (Pharsight Corporation, Cary, NC, USA). The following parameters were estimated:
maximal serum concentration (Cmax), time in which Cmax is reached (Tmax), area under the
concentration-time curve from time 0 to the last time analyzed (AUC), mean residence time (MRT),
clearance (Cl), volume of distribution (V) and half-life in the terminal phase (t1/2). Furthermore,
the relative oral bioavailability (Fr %) of resveratrol was estimated by the following equation:
Fr (%) = (
AUCoral
AUCiv
)× 100 (4)
where AUCi.v. and AUCoral were the areas under the curve for the iv and oral administrations,
respectively.
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4.9. In Vitro-In Vivo Correlations (IVIVC)
IVIVC were investigated by plotting a point-to-point between the amount of resveratrol released
(FRD) from nanoparticles vs. the fraction of resveratrol absorbed (FRA) calculated from the mean
plasma concentration-time inputs using the Wagner-Nelson equation [49]:
FRA =
Ct + k× AUC0−t
k× AUC0−∞ (5)
where Ct is the plasma concentration at a time t, k is the elimination rate constant, AUC0–t is the area
under the curve of the resveratrol plasma levels from 0 to time t, and AUC0–∞ is the area under the
curve from 0 to infinity.
Then, linear regression analysis was applied and the coefficient of determination (R2) calculated.
4.10. Statistical Analysis
Data are expressed as the mean ± standard deviation (SD). The non-parametric Kruskall-Wallis
followed by Mann-Whitney U-test was employed to investigate statistical differences. p < 0.05 was
considered to be statistically significant. All data processing was performed using Graph Pad® Prism
statistical software.
5. Conclusions
Resveratrol can be successfully encapsulated into casein nanoparticles. These carriers displayed
interesting properties for the oral administration of this polyphenol. First, casein nanoparticles released
resveratrol following a zero-order kinetic and the release rate was not affected by pH conditions.
Second, casein nanoparticles promoted the absorption of resveratrol offering sustained levels of the
polyphenol in plasma for at least 8 h. Consequently, the oral bioavailability of resveratrol when
encapsulated in casein nanoparticles was calculated to be close to 26.5%. Finally, a level IVIVC was
found between in the amount of resveratrol released from nanoparticles and the percentage orally
absorbed. This fact would be related with the capability of casein nanoparticles to both reach the
surface of the gut epithelium and control the release rate of resveratrol, promoting its absorption and
oral bioavailability.
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Abbreviations
AUC Area under the curve
Cl Clearance
Cmax peak plasma concentration
DAPI 4′,6-diamidino-2-phenylindole
E.E. encapsulation efficiency
Fr relative oral bioavailability
FRA fraction of resveratrol absorbed
FRD fraction of resveratrol released
IVIVC In vitro-in vivo correlations
LR-NP Lumogen red-loaded casein nanoparticles
MRT mean residence time
NP-C empty casein nanoparticles
NP-NOTA-Ga casein nanoparticles radiolabeled with Gallium-67
PCS photon correlation spectroscopy
PDI polydispersity index
PEG polyethylene glycol 400
Rsv resveratrol
Rsv-IV resveratrol solution intravenously administered
Rsv-NP-C resveratrol-loaded casein nanoparticles
Rsv-Sol solution of resveratrol in a mixture of PEG 400 and water
Rsv-Susp aqueous suspension of resveratrol
SGF simulated gastric fluid
SIF simulated intestinal fluid
t1/2 half-life of the terminal phase
Tmax time to reach plasma concentration
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